HomeInvestors & MediaNews
- Presentation on Grabody-T based Bispecific Antibody Poster
April 10, 2025, ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, announced that it will present preclinical data on YH32364 (ABL104) in poster format at the American Association for Cancer Research (AACR) annual academic conference. The poster will be jointly presented by ABL Bio and its partner company, Yuhan Corporation.
The AACR annual academic conference is one of the most prestigious cancer conferences in the world, held regularly each year. It brings together global pharmaceutical and biotech companies as well as industry experts to share the latest research outcomes. This year's AACR is taking place from April 25th to 30th (local time) in Chicago, USA.
The bispecific antibody YH32364 (ABL104), to be presented by ABL Bio and Yuhan, simultaneously targets Epidermal Growth Factor Receptor (EGFR) and 4-1BB, a co-stimulatory receptor involved in T cell activation. EGFR, when mutated, can activate tumor cell signaling pathways and promote tumor growth, making it a key target in cancer drug development. The title of the ABL104 poster is "YH32364 (ABL104), a bispecific antibody against EGFR and 4-1BB, demonstrates potent anti-tumor efficacy through tumor-directed 4-1BB agonism," and is scheduled to be unveiled on April 29th.
Sang Hoon Lee, CEO of ABL Bio said “We are pleased to introduce our pipeline incorporating Grabody-T, ABL Bio’s 4-1BB-based bispecific antibody platform, at AACR. Grabody-T is designed to activate T cells only within the tumor microenvironment, where tumor cells are present, reducing the inherent side effects of 4-1BB monoclonal antibodies while enhancing anti-tumor efficacy. Please look forward to this year’s AACR.”